

Research Article

Assessment of Thyroid functions in a sample of Pregnant Women in El-Minia University Hospital

Assmaa K. Ahmad*, Fatma Al-Sayed*, Ghada M. Al-Sagheer*,
Salama R. Abdul-Rahim** and Abdul-Aziz A. Abdallah*

* Department of Endocrinology, Internal Medicine, El-Minia University

** Departement of biochemistry, El-Minia University School of Medicine, El-Minia, Egypt

Abstract

Background: About 3 to 6% of pregnant women suffer from any variety of thyroid disorders and timely intervention can be done if detected early.⁽¹⁾ Pregnancy may affect the course of thyroid disorders and, conversely, thyroid diseases may affect the course of pregnancy.⁽²⁾ During gestation, a significant amount of TPO-Ab- and/or TGAb- positive women are at risk of developing hypothyroidism, since they have lower thyroid function reserve.⁽³⁾ **Aim of the study:** The aim of this study is to detect the presence of thyroid function abnormalities and thyroid autoantibodies in a sample of pregnant women to detect if there is a relation between the presence of these thyroid autoantibodies and the abnormalities of thyroid functions. **Subject and Methods:** The study assesses the level of thyroid hormones and thyroid autoantibodies in 11 pregnant women up to 13 week of gestation. **Results:** The present study revealed an abnormality in TSH level as it decreased in 4 pregnant women (36%) and raised in 6 women (54%). Thyroid autoantibodies were positive in 14 pregnant women (55.6%) as the anti TG antibody was positive in 7 pregnant women (28%) and the anti TPO was positive in 11 pregnant women (45.5%). **Conclusion:** Normal thyroid function during pregnancy is essential to ensure delivery of a healthy baby, which may be achieved with frequent monitoring of thyroid function during gestation and cautious adjustment of medications during treatment.

Key words: pregnancy, thyroid functions, thyroid autoantibodies.

Introduction

Thyroid hormone plays a role in brain development during the fetal period, as different parts of the brain are differentially sensitive to thyroid hormone at any one time during development, and the sensitivity to thyroid hormone is controlled, in part, by local control of hormone production⁽⁴⁾. The thyroid abnormalities during the first trimester of pregnancy should be under specific and particular pregnancy medical care, due to fetus physiological demand particularly physical, mental and brain developments. Therefore, evaluation of thyroid function tests during pregnancy is of great importance to prevent the above abnormalities⁽⁵⁾

The most frequent thyroid disorder in pregnancy is maternal hypothyroidism. It is associated with fetal loss, placental abruptions,

pre-eclampsia, preterm delivery and reduced intellectual function in the offspring.⁽⁶⁾

Positive thyroid peroxidase Antibody (TPO-Ab) and/or antithyroglobulin antibody (TG-Ab) test results are found in approximately 6% of euthyroid pregnant women. However, a thyroid autoantibody prevalence of up to 16% has been found in pregnant populations.⁽⁷⁾ At parturition, 67% of thyroid antibody-positive mothers have been reported to have high TSH values. During gestation, a significant amount of TPO-Ab- and/or TGAb- positive women are at risk of developing hypothyroidism, since they have lower thyroid function reserve⁽⁸⁾.

Chronic autoimmune thyroiditis is the most important cause of hypothyroidism in pregnant women, and up to 90% of women with hypothyroidism during pregnancy are positive for thyroid antibodies.⁽⁹⁾

Because many women remain asymptomatic, particular attention is required from the obstetrical care providers for this condition to be diagnosed and to evaluate more systematically thyroid function when women attend the prenatal clinic for the first time. Only thyroid function tests confirm the diagnosis.⁽¹⁾

Subjects and methods

This cross sectional study was conducted at in the outpatient clinics of Gynecology Obstetric Hospital El-Minia University in the period from November 2011 to November 2012, eighty eight pregnant women up to gestational age of 13 weeks selected randomly during the study period. Pregnant women were excluded if they already had thyroid disorders, receiving medical treatment for thyroid disorders, morbid obesity, history of ovarian hormonal therapy and women with Chronic medical disease (renal, hepatic, cardiac and autoimmune). Critically ill women were also excluded. All pregnant women were subjected to the following: Full history taking with respect to maternal age (over or under 35 years as women over 35 years are at increased risk to develop thyroid disorder during pregnancy⁽¹⁾, parity status (primigravida, multipara and grand multipara > 5 pregnancy)⁽¹⁾ and if there was history of Abortion and menstrual history. Thyroid symptoms were also asked for as defined by Paul et al., 2013⁽¹⁾ All participants were subjected to the following investigations. Hemoglobin level, fasting blood glucose, serum creatinine, thyroid function test (free T₄, free T₃, TSH). Measurement of thyroperoxidase antibodies (ATPO) and antithyroglobulin antibodies (ATG) levels by enzyme linked immunosorbent assay [ELISA].

Laboratory studies

Blood Sampling and Processing: 5ml venous blood were drawn for routine laboratory assessments: Two ml of venous blood on EDTA containing tube for fasting blood glucose, hemoglobin level, serum creatinine determined by spectrophotometer. 3 ml of the Collect blood specimens centrifuged and separate the serum immediately. Specimens had stored frozen at (-20°C). Prior to assay, frozen sera was completely thawed and mixed well.

Principle of TSH assesement:

The assay system utilize a unique monoclonal antibody directed against a distinct antigenic

determinant on the intact TSH molecule. Mouse monoclonal anti-TSH antibody is used for solid phase (microtiter wells) immobilization and a goat anti-TSH antibody is in the antibody-enzyme (horseradish peroxidase) conjugate solution. The normal range in the first trimester 0.05-2.0 uIU/ml.⁽¹⁾

Free Tri iodothyronine (T₃) level: using ELISA kits supplied from (The Diagnostic Automation Inc. company) in which cut off value equal to 1.5 - 4.5 pg/ml.

Free Thyroxine (T₄) level: using ELISA kits supplied from (Chemux Bio Science, Inc. Company, USA) in which cut off value equal to 0.65-1.95 ng/dL.

ANTI-TGA Titer Assay

Principle of the Test: Diluted patient serum is added to wells coated with purified TG recombinant antigen. TG specific antibody, if present, binds to the antigen. The intensity of the color generated is proportional to the amount of TG specific antibody in the sample. The normal range of ATGA index < 1.5 equal to < 50 IU/ml⁽¹⁾.

ANTI-TPO Titer Assay

Principle of the test: Diluted patient serum is added to wells coated with purified TPO recombinant antigen. TPO IgG specific antibody, if present, binds to the antigen. The enzyme. The intensity of the color generated is proportional to the amount of IgG specific antibody in the sample. The normal range of Anti TPO index < 1.5 equal to < 50 IU/ml.⁽¹⁾

Statistical Analysis

Data entry and analysis were done using software SPSS version 19, and microstats program. Graphics were done using Excel. Quantitative data were presented by mean and standard deviation, while qualitative data were presented by frequency distribution. Student t-test, and Z test used. The probability of less than 0.05 was used as a cut off point for all significant tests.

Results

The present study was conducted at Minia University in the out-patient clinics of Gynecology Obstetric Hospital, 88 pregnant women up to gestational age of 13 weeks selected randomly during the study period from

November 2011 to November 2012. The baseline characteristics of the 88 enrolled pregnant women were as follow. Their mean age was 26.7 yrs ± 6.4. 23.9% (21 pregnant women) were primigravida, 09% (02 pregnant women) were multipara and 10% (17 pregnant women) were grand multipara (more than 0 pregnancies). 21.6 %⁽¹⁴⁾ had history of previous abortion. Their gestational age was 37-38 weeks with mean (37.3±1.90)

TSH level was raised in 0 women (0.0%) and decreased in 4 pregnant women (4.5%). Thyroid autoantibodies were positive in 24 pregnant women (27.3%). As the anti TG antibody was positive in 7 pregnant women (7.9%) and the anti TPO was positive in 18 pregnant women (20.5%) **table 1**.

Table 2 shows the correlation between clinical data and laboratory results of the studied group. TSH, TG Ab and the TPO Ab was negatively correlated with gestational age. In addition TPO Ab was negatively correlated BMI whereas the TG Ab was negatively correlated with the maternal age. The other laboratory data showed insignificant correlation results.

TSH abnormalities were mainly in multiparous women as it raised in 4.5% (4 multiparous) and decreased in 0.0% (0 multiparous). TPO ab was elevated in 21.2%⁽¹¹⁾ multi-para and TGA ab was elevated in 0.6%⁽⁰⁾ multiparous. However these changes did not achieve statistically significant results.

The TPO ab positivity had no relation to the abnormalities in the TSH level as the TPO was positive in 20.0% (18 pregnant women) 2 of them had raised TSH and the others had normal TSH. The same was observed for the TGA ab and TSH level.

There was a significant relation between the TG ab and the T4 level as the p value was 0.02 as shown in table 3.

Tables (4); revealed the correlation studies between the laboratory parameters and clinical variables. Plasma TSH showed significant correlation with anti-TPO antibodies (P=0.020). Plasma T3 showed highly significant correlation with plasma T4 (P=0.000).TSH level in regressive analysis was related significantly with the anti TPO as shown in table 4.

Table (1): distribution of thyroid function and thyroid antibody according to normal values

Thyroid functions		Frequency (NO=88)	Percent
TSH	normal	79	89.8
	Raised	0	0.0
	decreased	4	4.5
T4	normal	78	88.6
	raised	8	9.1
	decreased	2	2.3
T3	normal	81	92.0
	Raised	7	7.9
	decreased	0	0.0
Anti TGA titer	Raised	7	7.9
	normal	81	92.1
Anti TPO titre	Raised	18	20.5
	normal	70	79.5

TSH= thyroid stimulating hormone, T3=tri-iodothyronine, T4=thyroxin Anti TGA=anti- thyroglobulin antibodies, Anti- TPO =Thyro-peroxidase antibodies

Table (2): Correlation between age and thyroid hormones in studied group

Variables		Maternal age	Gestational age	BMI
TSH	r	.19	.012-	.06
	p	.07	.9	.0
T ₃	r	-.23	.24	-.012
	p	.02*	.02	.2
T ₄	r	-.07	.181	.022
	p	.4	.09	.8
TPO-Ab	r	.008	-.02	-.07
	p	.9	.8	.0
TGA Ab	r	-.077	-.031	.010
	p	.0	.7	.8

Table (3): Relation between T₄ and TG ab

T ₄	TGA ab		Total	p
	raised	normal		
Normal	4	74	78	.03
	77.7%	90.2%	88.7%	
Decreased	1	1	2	
	17.7%	1.2%	2.3%	
Raised	1	7	8	
	17.7%	8.0%	9.1%	
Total	7	82	88	
	100.0%	100.0%	100.0%	

Table (4): Correlation between thyroid hormones and thyroid antibodies

		TSH	T ₄	T ₃	TGA ab	TPO ab
TSH	Pearson Correlation		-.172	.099	-.019	.239*
	Sig. (2-tailed)		.109	.307	.870	.020
	N		88	88	88	88
T ₄	Pearson Correlation	-.172		.402**	.070	.072
	Sig. (2-tailed)	.109		.000	.487	.003
	N	88		88	88	88
T ₃	Pearson Correlation	.099	.402**		.149	.171
	Sig. (2-tailed)	.307	.000		.177	.133
	N	88	88		88	88
TGA ab	Pearson Correlation	-.019	.070	.149		.081
	Sig. (2-tailed)	.870	.487	.177		.400
	N	88	88	88		88
TPO ab	Pearson Correlation	.239*	.072	.171	.081	
	Sig. (2-tailed)	.020	.003	.133	.400	
	N	88	88	88	88	

Table (9): multiple regressive analyses for TSH

TSH	Standarized coefficient	T	Sig
	Beta		
Age	.277	1.491	.140
Gestational age	.000	.040	.964
Abortion	-.008	-.010	.708
Parity	.048	.303	.763
BMI	-.070	-.462	.740
Hb	-.027	-.230	.819
ATG-ab	-.044	-.392	.797
ATPO-ab	.203	2.278	.020




Figure (1): Distribution of thyroid functions & thyroid antibodies in the studied groups




Fig. 2: Relation between TSH and parity




Fig. 3: Correlation between TSH and anti-TPO antibodies

Discussion

There is a high incidence of thyroid dysfunction during pregnancy resulting in adverse maternal and fetal effects which may justify screening for thyroid function during early pregnancy⁽¹¹⁾. Evaluation of thyroid status in pregnancy requires an understanding of pregnancy-associated changes in thyroid function tests and how they vary by trimester⁽¹²⁾. During pregnancy and after delivery, the maternal thyroid gland faces several metabolic, hemodynamic and immunologic changes. Thyroid autoimmunity ameliorates during pregnancy and aggravates after delivery^(13,14). The circulating levels of thyroid-binding globulin (TBG) are also increased by estrogen stimulation. On the other hand the increased renal clearance both fetal intake and placenta metabolism induce a relative decline in the availability of iodide⁽¹⁵⁾.

In the present study; 0.7% of subjects showed raised plasma TSH.

Measurement of serum TSH is the first-line screening variable for thyroid dysfunction in pregnancy⁽¹⁶⁾. Peripheral thyroid hormone values are highly different among laboratories, and there is a need for laboratory-specific gestational age-related reference ranges. The best laboratory assessment of thyroid function is a free thyroid hormone estimate combined with TSH^(17,18)

The prevalence of moderately elevated TSH levels consistent with subclinical hypothyroidism (4.0-10.0 IU/mL) was 23% in a cohort of 1,231 women pursuing assisted reproductive technologies⁽¹⁹⁾. There is a greater prevalence of subclinical hypothyroidism in women with delivery before 32 weeks. Higher maternal TSH levels even within the normal reference range are associated with an increased risk of miscarriages, fetal and neonatal distress and preterm delivery⁽²⁰⁾.

In the study of Dal-Lago et al., (2011) they found that the mean basal TSH serum levels were higher ($P < 0.001$) in repeated miscarriage women compared with the controls. A transient impairment of thyroid function in early pregnancy may be implicated in repeated abortions⁽²¹⁾.

The current study results differ from those of Stagnaro-Green et al., (2012)

who found that TSH values decline during the transition from pre-pregnancy to early pregnancy. Serum TSH levels decrease in the first trimester and increase in the second and third trimesters; however, not to pre-pregnancy levels⁽²²⁾.

In the current study; T4 showed significant inverse correlation with gestational age and history of previous abortions

Younger age and being in gestational weeks 1-8 were significant risk factors for hypo-

thyroidism. They suggested that the reference criteria need revision, and that pathology laboratories should adopt appropriate pregnancy-specific reference intervals⁽¹⁵⁾.

Several recent recommendations to use total thyroxine measurements in the diagnosis of thyroid function in pregnancy (in particular, "Clinical Practice Guidelines for Hypothyroidism in Adults," cosponsored by the American Thyroid Association and the American Association of Clinical Endocrinologists, which promote the use of Total over free Thyroid hormones⁽¹⁶⁾.

Accordingly FT assays that fully compensate for serum TBG concentrations should discriminate dysfunctionality from normality more efficiently than total hormone measurements, whether in pregnant or non-pregnant states. The difficulties in FT measurement arise from inconsistent calibration of present-day commercial assays. This finding questions the recommendation that total hormone assays should supersede the former in pregnancy⁽¹⁷⁾.

In the current study those women with raised titre of TPO antibodies were (20.0%) and those with raised titre of TG antibodies were (1.8%). T₄ showed significant correlation with TGA antibodies and insignificant one with anti-TPO antibodies. Meanwhile; T₃ showed insignificant correlation with both groups of antibodies. On the other hand TSH showed significant correlation with anti-TPO antibodies and insignificant one with anti-TGA antibodies. The current results agreed with those of Ashoor et al., (2010) as they found 16.8 % of pregnant women were positive for one or both anti-thyroid antibodies. This difference may be related to the difference in the numbers of both groups.⁽¹⁸⁾

At least 0-10% of women showed positive titre for thyroid antibodies and have an increased risk of developing a certain degree of thyroid insufficiency during pregnancy (Krassas et al., 2010).⁽¹⁹⁾

The results of the present result was much higher than that of Wang et al., (2011); who found that the TPO abs was positive in 9.6% of cases only⁽²⁰⁾. TPO-ab is suspected to be

associated with an increased risk of fetal loss, premature delivery and hypothyroidism⁽²¹⁾.

Acknowledgements:

We would like to thank our colleague in El-Minia hospital of obstetric and gynaecology for their cooperation in collection of the cases . we also would like to thank dr. Abid al Aziz Abed Alzahar for sharing in funding this research.

References

1. Glinoe D, Fernandez Soto ML, Bourdoux P, et al.: Pregnancy in patients with mild thyroid abnormalities: Maternal and neonatal repercussions. *J Clin Endocrinol Metab* 23:411, (1991).
2. Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot L, Glinoe D, Mandel SJ, Stagnaro-Green A: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2007; 92 (A) (Supplement): S1-S47
3. Glinoe D, Riahi M, Grun JP & Kinthaert J: Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders. *J Clin Endocrinol Metab*. 1994; 79(1): 197-204.
4. Zoeller RT, Rovet J.: Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings. *J Neuroendocrinol*. 2004 Oct; 16 (10):809-18 oct
5. LeBeau SO, Mandel SJ: Thyroid disorders during pregnancy. *Endocrinol Metab Clin N Am*. 2006; 20:117.
6. Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot L, Glinoe D, Mandel SJ, et al.: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2007; 92 (A) (Supplement): S1-S47.
7. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter TF, Luthy D, Gross S, Bianchi DW & D'Alton ME: Maternal thyroid hypofunction and pregnancy outcome. *Obstet Gynecol*. 2008; 112(1): 80-92.
8. Klein RZ, Haddow JE, Faix JD, Brown RS, Hermos RJ, Pulkkinen A & Mitchell ML: Prevalence of thyroid deficiency in

- pregnant women. *Clin Endocrinol (Oxf)*. 1991; 35(1): 41-6.
9. Spong CY et al.: Subclinical hypothyroidism: should all pregnant women be screened? *Obstet Gynecol*. 2000; 100:237.
 10. De Groot L, Abalovich M, Alexander E K: management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline *Clin Endocrinol Metab*. 2012; 97: 2043-2060.
 11. Creinin MD, Simhan HN: Can we communicate gravidity and parity better? *Obstet Gynecol*. 2009; 113(3):709-11.
 12. Paul A. Fitzgerald: *Endocrine Disorders Current Medical Diagnosis & Treatment Fifty – Second Edition* (2013)
 13. Glinioer D and C. A. Spencer: “Serum TSH determinations in pregnancy: how, when and why?” *Nature Reviews Endocrinology* 2010; vol. 6, no. 9, pp. 526-529.
 14. Feldt-Rasmussen U. Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. *Clin Chem*. 1996; 42:160-3.
 15. Franke WG; Schimming C; Wunderlich G.: Can thyroid peroxidase be used as a complementary tumor marker besides thyroglobulin? Preliminary experience with determination of TP₀ in differentiated thyroid carcinomas. *Anticancer Res* 1997; 17(5B):2999-3002.
 16. Julvez J, Alvarez-Pedrerol M, Rebagliato M, Murcia M, Forn J, Garcia-Esteban R, Lertxundi N, Espada M, Tardón A, Riaño Galán I, Sunyer J. Thyroxine levels during pregnancy in healthy women and early child neurodevelopment. *Epidemiology* 2013; Jan; 24(1):100-7.
 17. Milanesi A, Brent GA. Management of hypothyroidism in pregnancy. *Curr Opin Endocrinol Diabetes Obes* 2011; Oct; 18(5):304-9.
 18. Gaberek S, Zaletel K.: Thyroid physiology and autoimmunity in pregnancy and after delivery. *Expert Rev Clin Immunol* 2011; Sep; 7(9):1197-1206; quiz 1207.
 19. Karagiannis G, Ashoor G, Maiz N, Jawdat F, Nicolaides KH.: Maternal thyroid function at eleven to thirteen weeks of gestation and subsequent delivery of small for gestational age neonates. *Thyroid* 2011; Oct; 21(10):1127-31.
 20. Cignini P., Ester Valentina Cafà, Giorlandino C., Capriglione S., Spata A. and Dugo N: Thyroid physiology and common diseases in pregnancy: review of literature *J Prenat Med*. 2012; Oct-Dec; 16(4): 64-71.
 21. Balthazar U, Steiner AZ.: Periconceptional changes in thyroid function: a longitudinal study. *Reprod Biol Endocrinol* 2012; Mar 21; 10:20.
 22. Feldt-Rasmussen U, Bliddal Mortensen AS, Rasmussen AK, Boas M, Hilsted L, Main K.: Challenges in interpretation of thyroid function tests in pregnant women with autoimmune thyroid disease. *J Thyroid Res* 2011; Mar 10; 098712.
 23. Michalakis KG, Mesen TB, Brayboy LM, Yu B, Richter KS, Levy M, Widra E, Segars JH.: Subclinical elevations of thyroid-stimulating hormone and assisted reproductive technology outcomes. *Fertil Steril*. 2011; Jun 30; 95(6):2634-7. Epub Mar 31.
 24. Chang DL, Leung AM, Braverman LE, Pearce EN.: Thyroid testing during pregnancy at an academic Boston Area Medical Center. *J Clin Endocrinol Metab*. 2011; Sep; 95(9):E1402-6. Epub Jun 29.
 25. Lazarus JH.: Screening for thyroid dysfunction in pregnancy: is it worthwhile? *J Thyroid Res*. 2011; 297012. Epub Jun 8.
 26. Dal Lago A, Vaquero E, Pasqualetti P, Lazzarin N, De Carolis C, Perricone R, Moretti C.: Prediction of early pregnancy maternal thyroid impairment in women affected with unexplained recurrent miscarriage. *Hum Reprod* 2011; Jun; 26(6):1324-30. Epub 2011 Mar 23.
 27. Stagnaro-Green A, Pearce E.: Thyroid disorders in pregnancy. *Nat Rev Endocrinol*. 2012; Sep 20.
 28. Alkafajei A, Amarin Z, Alazaizeh W, Khader Y, Marji M.: Prevalence and risk factors for hypothyroidism in Jordanian women: comparison between different reference ranges. *East Mediterr Health J* 2012; Feb; 18(2):132-6.
 29. ATA/AACE Guidelines - Garber, JR., Rhoda H. Cobin, Hossein Gharib; James V. Hennessey, Irwin Klein, Jeffrey I. Mechanick, Rachel Pessah-Pollack, Peter A. Singer, Kenneth A. Woeber.: Clinical practice guidelines for hypothyroidism in

- adults: cosponsored by the american association of clinical endocrinologists and the american thyroid association. *endocrine practice* 2012; 18(6)-nov-dec.
30. Midgley JE, Hoermann R.: Measurement of total rather than free thyroxine in pregnancy: the diagnostic implications. *Thyroid*. 2013 Mar; 23(3):209-11.
31. Ashoor G, Nikos A. K, Akolekar R et al.: Maternal Thyroid Function at 11-13 Weeks of Gestation. *Fetal Diagn Ther*. 2010; 27:106-113
32. Krassas GE, Poppe K, Glinoe D.: Thyroid function and human reproductive health. *Endocrine Reviews*. 2010; 31: 702-700.
33. Wang WS.: Screening for thyroid disease during early pregnancy. *Eur. J. of endocrinol.*; 2011
34. Lepoutre T, Debiève F, Gruson D, Daumerie C.: Reduction of miscarriages through universal screening and treatment of thyroid autoimmune diseases. *Gynecol Obstet Invest*. 2012; 74(4):260-73.